This genotoxic damage is a potent stimulus for programmed successful therapy of a primary malignancy has been recogcell death, which in turn has been proposed to be the major generally been thought to be more commonly involved in topo II-related t-AML; a series of 35 pediatric patients with t-AML demonstrated 11q23 translocations to be eight times Introduction more common than 21q22 translocations. 4 There has been some speculation that this difference may be due to chemoThe development of secondary, or therapy-related acute myetherapy regimens emphasizing epipodophyllotoxins in the logenous leukemia (t-AML) in patients previously treated for pediatric series, while the adult series used more anthracya primary malignancy has become of increasing concern over clines. 2, 4 The MLL breakpoints identified in both de novo as the past several years. In general, two groups of t-AML assowell as t-AML patients cluster within a relatively small 8.3 kb ciated with distinct clinical and cytogenetic characteristics breakpoint cluster region (bcr); 5,13 the AML1 breakpoints assohave been distinguished. 1 The first group is associated with ciated with t-AML have been less extensively evaluated. Both treatment regimens which include alkylating agents, shows a t(8;21)(q22;q22) and t(3;21)(q26;q22) translocations dispeak incidence after a latency period of approximately 4-6 rupting the AML1 locus have been associated with t-AML; the years, and is often preceded by a preleukemic or myelodyst(8;21) translocation breakpoints involving AML1 most complastic phase.
generally been thought to be more commonly involved in topo II-related t-AML; a series of 35 pediatric patients with t-AML demonstrated 11q23 translocations to be eight times Introduction more common than 21q22 translocations. 4 There has been some speculation that this difference may be due to chemoThe development of secondary, or therapy-related acute myetherapy regimens emphasizing epipodophyllotoxins in the logenous leukemia (t-AML) in patients previously treated for pediatric series, while the adult series used more anthracya primary malignancy has become of increasing concern over clines. 2, 4 The MLL breakpoints identified in both de novo as the past several years. In general, two groups of t-AML assowell as t-AML patients cluster within a relatively small 8.3 kb ciated with distinct clinical and cytogenetic characteristics breakpoint cluster region (bcr); 5,13 the AML1 breakpoints assohave been distinguished. 1 The first group is associated with ciated with t-AML have been less extensively evaluated. Both treatment regimens which include alkylating agents, shows a t(8;21)(q22;q22) and t(3;21)(q26;q22) translocations dispeak incidence after a latency period of approximately [4] [5] [6] rupting the AML1 locus have been associated with t-AML; the years, and is often preceded by a preleukemic or myelodyst(8;21) translocation breakpoints involving AML1 most complastic phase. [1] [2] [3] Cytogenetic analysis of these cases often monly occur within a 30 kb region encompassing AML1 demonstrates loss of genetic material involving the long arm exons 5 and 6. 12, 14, 15 While fewer of the t(3;21)(q26;q22) of chromosome 5 or 7.
breakpoints have been precisely mapped, there are reports The second group of t-AML is associated with treatment indicating that these breakpoints typically occur between regimens incorporating agents directed against eukaryotic exons 5 and 6 or exons 6 and 7.
12, 16 topoisomerase II (topo II). [1] [2] [3] [4] [5] [6] [7] DNA topoisomerases are ubiquiThe evidence available strongly suggests that these translotously expressed nuclear proteins which catalyze the topologications associated with topo II inhibitor therapy are probably cal changes necessary for DNA replication and transcription.
induced by treatment with the topo II inhibitor, [1] [2] [3] [4] [5] [6] [7] 17 although Eukaryotic topo II functions by catalyzing a transient doublethe molecular pathway(s) by which topo II inhibitors induce strand DNA break with the formation of enzyme-DNA covalchromosomal translocations have not been defined. As a first ent intermediates, followed by strand passage and religation of approximation, the simplest model to describe the molecular the DNA substrate. 8, 9 Topo II inhibitors stabilize the transient events leading to a reciprocal chromosomal translocation enzyme-DNA intermediate (the 'cleavable complex'), involves double-strand DNA cleavage followed by abnormal resulting in an accumulation of DNA double-strand breaks. 8, 9 repair, with re-ligation of the broken DNA duplex to a discontiguous genomic region. Recently, we reported that site-specific DNA cleavage within the 8.3 kb MLL bcr can be induced icin or etoposide, 18 and speculated that topo II inhibitor-induced DNA cleavage within the MLL bcr might be the initial Indirect end-labelling was performed using 32 P-labeled probes. 21 The probes were labeled by the random priming techstep leading to the development of an MLL translocation. This study describes the induction of site-specific DNA cleavage nique, using a Prime-It II kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol, and hybridized to within the AML1 bcr induced by topo II inhibitors, and contrasts this cleavage with that induced within the MLL bcr. Southern blots as previously described. 18 Final washing conditions were 0.1% sodium dodecyl sulfate (SDS)/0.1 × SSC (1 × SSC = 0.15 mol/l NaCl and 0.015 mol/l sodium citrate) at 52°C for all probes except the 0.4SS, which was washed at Materials and methods 65°C. Autoradiography of blots was performed for 2-5 days at −70°C with an intensifying screen.
Patient samples and cell lines Cell culture was performed using RPMI 1640 supplemented glutinin (BRL). Cells were then washed and resuspended in supplemented 1640 medium, and either treated with etopowith 10% fetal bovine serum (FBS; GIBCO, Grand Island, NY, USA), L-glutamine (2 mM), penicillin (100 U/ml), and streptoside or DMSO for 16 h. All drugs were purchased from Sigma, and either dissolved in DMSO (etoposide (VP16), actinomycin mycin (100 g/ml), except for KG-1 cells, which were maintained in Iscove's modified Dulbecco's medium (GIBCO), D, amsacrine (m-AMSA)) or sterile water (doxorubicin). Final drug concentrations used in the experiments were 10 M etosupplemented in the same manner as described for RPMI 1640.
poside (with the exception of the initial experiment shown in Figure 1a , where 100 M etoposide was used), 0.3 g/ml doxorubicin, 50 ng/ml actinomycin D and 30 M m-AMSA.
DNA isolation and Southern blotting
Genomic DNA was isolated using a salting-out extraction proResults and discussion cedure, as previously described. 18 Ten micrograms of genomic DNA were digested with the indicated restriction Genomic DNA cleavage within the AML1 locus induced by topo II inhibitors enzyme (BRL, Gaithersburg, MD, USA), size-fractionated on 0.8% agarose gels containing 1.0 g/ml ethidium bromide, photographed, denatured, neutralized, and transferred to Since site-specific double-strand DNA cleavage within the MLL breakpoint cluster region can be induced by topo II nitrocellulose membranes. DNA was immobilized by UV crosslinking.
inhibitors, it was of interest to investigate whether this was a unique observation restricted to the MLL locus, or a more generalizable phenomenon. We had previously searched for site-specific cleavage inducible by topo II inhibitors at several Indirect end-labeling loci frequently disrupted by chromosomal translocations, including SCL/TAL, ENL, AF-6, c-myc, and the T cell receptor The MLL probe used in this study was a 0.2 kb HhaI-BamHI cDNA fragment including exons 9 to 11 (probe 0.2HB; ␤ and ␦ (TRCB and TRCD), and were unable to detect specific DNA cleavage at these loci. 18 Of particular interest to us was nucleotides 4207-4423 of Genbank accession No.L04731). The AML1 probes were a 0.24 kb HindIII-EcoRI cDNA fragto discern whether a similar event would be observable in other breakpoint cluster regions involved in t-AML associated ment including exons 5 and 6 (probe C6E6H2), 14 and a 0.4 kb SmaI-SstI genomic fragment (probe 0.4SS) covering the 3Ј half with topo II inhibitor treatment. The AML-1 locus, located at chromosome 21q22 and recurrently involved in t-AML assoof exon 6 and extending to an SstI site 260 bp downstream of exon 6 (see Figure 3a) . The 0.4SS genomic AML1 fragment ciated with topo II inhibitor therapy, was a reasonable candidate locus. was isolated from a human placental phage library (Strategene, La Jolla, CA, USA) using standard techniques. 19 The 21q22 breakpoints involved in t(8;21) translocations cluster within a limited 30 kb region of the AML1 locus and The retinoic acid receptor ␣ (RARA) cDNA probe encompassing portions of RARA exons 2, 3 and 4 (nucleotides can generally be identified by Southern blot hybridization to a cDNA probe containing AML1 exon 5 and 6 sequences. 22 103-526 of Genbank accession No. X06614) was isolated from the pCMX-hRAR␣ plasmid. 20 We used the technique of indirect end-labeling 21 to search for evidence of site-specific DNA cleavage within this AML1 bcr not shown). Similar to the situation seen at the MLL locus, we suspected that one end of the novel DNA fragment was induced by topo II inhibitor treatment. Figure 1a shows a genomic Southern blot hybridized to the 0.2HB MLL cDNA probe produced by cleavage with the restriction enzyme (SstI or BamHI), while the other end of the novel fragment was proand reprobed with the C6E6H2 AML1 cDNA probe. Partial maps of the MLL and AML1 loci are presented in Figures 1b duced by etoposide treatment. Since the dose of 100 M etoposide used in our initial experiments represents a concenand 1c. In addition to the germline fragments, a novel 0.85 kb fragment produced by etoposide treatment of the Molt4 cell tration of etoposide well above clinically relevant concentrations, we reduced the amount of etoposide in our line hybridized to the C6E6H2 probe. Furthermore, a prolonged exposure of the autoradiograph (shown in Figure 1a ) subsequent experiments to 10 M. In addition, it is important to note that the cleavage induced by topo II inhibitors is demonstrates a faint band at 0.85 kb in the PBMC and BALL1 etoposide-treated lanes as well as in the patient sample RUPN not necessarily a direct effect of topo II inhibitor treatment, such as cleavable complex formation, but may instead be a No. 78. A BamHI digest of the same DNA samples, hybridized to the C6E6H2 AML1 probe showed a novel 2.2 kb fragment downstream effect of the DNA damage caused by the topo II inhibitor. produced by etoposide treatment of the Molt4 cell line (data Comparison of etoposide-induced cleavage at the AML1 locus with that previously identified at the MLL locus reveals several notable differences. First, the MLL site seemed to be more 'sensitive' than the AML1 site, as etoposide-induced cleavage is clearly visualized in the PBMC, BALL1, and RUPN No. 78 lanes hybridized to the MLL probe, while etoposideinduced cleavage can only be detected upon prolonged exposure of the autoradiograph when the filter is rehybridized to the AML1 probe. However, the Molt4 cell line seemed to be equally sensitive to cleavage at either locus. Second, the AML1 cleavage site may be less specific than the MLL cleavage site, as additional, fainter bands are clearly seen in the Molt4 etoposide-treated lane, suggesting the presence of additional, minor cleavage sites, as opposed to the MLL locus, where we have not detected any additional bands. The etoposide-induced cleavage seen in the Molt4 cell line was not unique to this cell line or to lymphoid cell lines, as the CEM and Jurkat cell lines (both lymphoid) as well as the myeloid cell line KG-1 show a pattern of etoposide-induced cleavage identical to that seen with the Molt4 cell line (data not shown). In contrast, using similar assay conditions, we were unable to detect site-specific cleavage in the cell lines HEL, K562, and H69 (data not shown). Although this may be a coincidental finding, it is intriguing to note that the AML1 cleavage site seems both less sensitive and less specific than the MLL cleavage site, and MLL translocations seem in general to be more common than AML1 translocations following topo II inhibitor treatment. specific cleavage within the AML1 locus when Molt4 cells are treated with either etoposide, doxorubicin, actinomycin D or m-AMSA. Additionally, the T cell line CEM showed an identencompass either exon 5 or 6, and be located 2.2 kb from a BamHI restriction site. We therefore focused our search for ical pattern of AML1 site-specific cleavage when treated with either doxorubicin or etoposide (data not shown), demonstratthe topo II inhibitor-induced cleavage site in the regions nearby exons 5 and 6. A restriction map of the region flanking ing that the AML1 site-specific cleavage was neither unique to the T cell line (Molt4) nor the topo II inhibitor (etoposide) AML1 exon 6 was developed and is shown in Figure 3a ; hybridization of a single copy SmaI-SstI genomic fragment used in our initial experiments.
Identical cleavage pattern is induced by several topo
(0.4SS) to a Southern blot of genomic DNA extracted from Molt4 cells treated with doxorubicin and subsequently restricted with either SstI, BamHI, or EcoRI is shown in Figure 3b .
Fine mapping and sequence analysis of the AML1 cleavage site
Novel fragments of 0.85 kb, 2.2 kb and 3.9 kb are seen in the SstI, BamHI and EcoRI lanes, respectively. In each case, one end of the novel fragment is produced by restriction enzyme In our initial experiments we used a cDNA probe which included AML1 exon 5 and 6 sequences; this probe covered cleavage, and the other end is produced by specific cleavage of genomic DNA induced at the site indicated in Figure 3a by about 30 kb of genomic sequence. To develop a finer map of the region where AML1 topo II inhibitor-induced cleavage the topo II inhibitor; all three restriction enzyme digests map the cleavage site to the same region. An experiment treating occurred, and to confirm our preliminary mapping with additional probes, we obtained several AML1 genomic phage Molt4 cells with etoposide rather than doxorubicin yielded identical results (data not shown). Interestingly, the AML1 clones by screening a human placental library with the C6E6H2 AML1 cDNA probe. Several hybridizing clones were breakpoint cluster region has been divided into two contiguous BamHI fragments of 20 kb and 11 kb; most of the breakidentified, purifed and mapped; single copy genomic probes were isolated from these clones.
points in patients with the t(8;21) disrupt the 20 kg fragment; 23 the induced cleavage site reported here also involves the Since AML1 exons 5 and 6 are both located within 2 kb of BamH1 restriction sites, 15 and the topo II inhibitor-induced 20 kb BamHI fragment. The 8.3 kb MLL breakpoint cluster region has been comfragment was 2.2 kb when restricted with BamHI, we reasoned that the site-specific cleavage site should both pletely sequenced, 24 and contains a single perfect (18/18) 494 match for the preferred topo II consensus cleavage site as described by Spitzner and Muller. 25 This consensus sequence (5Ј-A/GNT/CNNCNNGT/CNGG/TTNT/CNT/C-3Ј) is quite degenerate, with eight of the 18 bases being 'N'; and was derived from in vitro experiments using naked DNA. 25 With these caveats in mind, it is interesting to note that the induced cleavage site within the MLL bcr maps to the only perfect conesnsus sequence. 18 Since the AML1 cleavage site is approximately 0.85 kb 5Ј of the SstI site shown in Figure 3a , we sequenced genomic DNA 1.0 kb 5Ј of this SstI site and searched this sequence for matches to the consensus topo II cleavage sequence. While there were no perfect matches for the consensus topo II cleavage sequence found, a 16/18 match for the topo II consensus cleavage site was identified 890 bp 5Ј of the SstI site (Figure 4) , close to the site-specific cleavage site, and within the margin of error for size estimation on genomic DNA Southern blots.
Site-specific cleavage cannot be detected within RARA intron 2
Given the identification of site-specific MLL and AML1 cleavage inducible by treatment with topo II inhibitors, we searched for a cleavage site within the RARA locus. Although not as frequent as 11q23 or 21q22 abnormalities, t-AML with t(15;17)(q23;q21) translocations involving the PML and RARA loci have been reported following therapy with topo II inhibitors.
1,2 We focused on RARA intron 2 as a likely site for topo II inhibitor-induced cleavage for the following reasons. First, t(15;17)(q23;q21) translocation breakpoints generally cluster within RARA intron 2, 26 while the breakpoints within the PML locus seem to be more widely dispersed. In addition, two less common variant translocations associated with acute promyelocytic leukemia, the t(5;17)(q32;q12) and t(11;17)(q23;q21), involve the RARA locus. Therefore, the RARA locus would seem to be the common denominator in acute promyelocytic leukemia. We searched for site-specific cleavage within the RARA locus by reprobing the blot used for Figure 2 with an RARA cDNA which flanks exons 2 and 3 (using the exon numbering scheme reported by Lafage-Pochitaloff et al, 27 which does not include an intervening alternately spliced exon). Based on the genomic restriction map of RARA intron 2, we also assayed genomic DNA from etoposide-treated cells using KpnI, HindIII, and XbaI restriction digests in addition to the BamHI and SstI digests which had demonstrated MLL and AML1 topo II inhibitor-induced cleavage sites. We assayed several myeloid (KG1, HL60, ML1, K562, HEL) and several lymphoid (Molt4, CEM, Jurkat, BALL1) cell lines. In no case did we detect site-specific DNA cleavage induced by topo II inhibitors within RARA intron 2 (data not shown).
In summary, we have identified a region within the AML1 locus that, similar to the MLL bcr, is highly sensitive to doublestrand DNA cleavage induced by topo II inhibitors. This DNA ribosomal RNA, 29 or in less complex genomes such as Droso-0.85 kb, 2.2 kb and 3.9 kb in addition to the germline fragments are phila melanogaster. 30 However, although regions susceptible seen in SstI, BamHI and EcoRI lanes respectively, and indicated with arrows.
to topo II-induced DNA cleavage are likely to be dispersed throughout the genome, 25 the only regions thus far identified which undergo a degree of site-specific DNA cleavage 
